English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/87729
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


New aromatic iminoimidazolidine derivatives as α1-adrenoceptor antagonists: A novel synthetic approach and pharmacological activity

AuthorsDardonville, Christophe ; Goya, Pilar ; Rozas, Isabel; Alsasua, Ángela; Martín, M. Isabel
Issue Date2000
PublisherPergamon Press
CitationBioorganic and Medicinal Chemistry 8: 1567- 1577 (2000)
AbstractThe design, synthesis and α1-adrenoceptor antagonism of a series of bis-imidazoline (1a, 2a, 3a and 4a)Figure 2New families of compounds prepared in this work: (a) bis-2-iminoimidazolidinium derivatives, and (b) bis-guanidinium derivatives.Scheme 1 and bis-guanidine (1b, 2b, 3b and 4b) diphenyl derivatives are reported. All of these compounds fulfil the conditions of the most recent pharmacophore proposed for α1-adrenoceptors and found in the literature. Besides, a novel synthetic approach to the preparation of 2-(arylimino)imidazolidine derivatives is described. All the tested compounds, except the bis-guanidinium derivative 3b, inhibit the contractile responses induced by noradrenaline in aortic rings of rat and rabbit in a dose-dependent manner. Our results indicate that, even though some discrepancies are observed in terms of the α1 subtype targeted by this new family of compounds, they show an interesting profile as antagonists of α1-adrenoceptors and a new prototype, compound 1a, has been found deserving further development. Copyright (C) 2000 Elsevier Science Ltd.
Identifiersdoi: 10.1016/S0968-0896(00)00089-4
issn: 0968-0896
e-issn: 1464-3391
Appears in Collections:(IQM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.